Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double-blind and Placebo-controlled Study of Once Daily BI 201335 120 mg for 12 or 24 Weeks or BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Patients With Genotype 1 Chronic Hepatitis C Infection
Brief Summary: The objective of this trial is to evaluate the efficacy and safety of two different treatment regimens with BI 201335, both in combination with PegIFN/RBV) as compared to standard of care (SOC) with PegIFN/RBV alone.


Options:
A: Arm Label: PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV | Arm Label: BI 201335 for 12 or 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI 201335 | Arm Label: Placebo and PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV, Drug: Placebo | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 for 12 or 24 weeks, PegIFN/RBV, Placebo and PegIFN/RBV | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and PegIFN/RBV
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
C: Arm Label: Phase 2a: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2a: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2b: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2b: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Phase 2a: Arm 1 | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2a: Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Peginterferon Alfa-2a; Assigned to Arm(s): Phase 2a: Arm 1, Phase 2a: Arm 2, Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Peginterferon Alfa-2a; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Phase 2a: Arm 1, Phase 2a: Arm 2, Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Phase 2b: Arm 1
D: Arm Label: SOF+RBV+placebo; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV, Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV, SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): SOF+RBV+placebo | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): SOF+RBV+placebo

Answer: A